Intra-Cellular Therapies to Present at the 35th Annual J.P. Morgan Healthcare Conference

News
1

Intra-Cellular Therapies to Present at the 35th Annual J.P. Morgan Healthcare Conference

NEW YORK, Jan. 04, 2017 (GLOBE NEWSWIRE) – Intra-Cellular Therapies, Inc. (Nasdaq:ITCI) a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco at the Westin St. Francis Hotel. The presentation is scheduled for Thursday, January 12, 2017 at 11:00 am PST (2:00 pm EST).

The live and archived webcast can be accessed under “Events & Presentations” in the Investor Relations section of the Company’s website at www.intracellulartherapies.com. Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.

About Intra-Cellular Therapies

Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson’s and Alzheimer’s disease. The Company is developing its lead drug candidate, ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, including Alzheimer’s disease, depression and other neuropsychiatric and neurological disorders. ITI-007, a first-in-class molecule, is in Phase 3 clinical development for the treatment of schizophrenia, bipolar depression and agitation associated with dementia, including Alzheimer’s disease. The Company is also utilizing its phosphodiesterase platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders.

1 Like
2

means they can come…!!!

3

ITI-007, a first-in-class molecule, is in Phase 3 clinical development for the treatment of schizophrenia, bipolar depression and agitation associated with dementia, including Alzheimer’s disease.

Except it’s not. :smile:

1 Like
4

means…???

5

It’s not in phase 3.

1 Like
6

which phase is it…???

7

It’s not in any phase. It failed phase 3.

1 Like
8

yes this could be failed,another wiill come just wait and watch…~~~~

1 Like
9

I would really like to see this med make it to the market. But they may be presenting info on the other ITI drug for depression or just trying to recoup their losses from ITI -007.

10

The company presents at all the conferences to keep its stock price up, in case it has to sell more stock. Often it presents no new info.
ITI-007 may be in Phase 3 for a bipolar trial.

1 Like
11

Any chance this might still get approved for psychosis? Or is it another failed drug at this point?

12

There is a chance it could eventually get approved for bipolar or schizophrenia. I don’t know if the company has enough money for another Phase 3 schizophrenia trial.

1 Like
13

Is there any point it will get any approval cuz it didn’t proved effective at all…!!!

14

I think it was somewhat effective but the placebo was also just as effective in the last Phase 3 trial for sz.

1 Like